ED
AMRN

Exane Derivatives’s Amarin Corp AMRN Stock Holding History

Exane Derivatives’s Portfolio AMRN Stock Details AMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-470
Closed -$39.6K – 829
2020
Q3 		$39.6K Sell
470
-16
-3% -$1.92K 0.01% 387
2020
Q2 		$67.3K Buy
486
+120
+33% +$16.5K 0.02% 334
2020
Q1 		$29.3K Buy
+366
New +$122K 0.01% 392

Other funds holding AMRN

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
SI
SCP Investment Orinda, California $90.3M AUM 31.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Exane Derivatives's AMRN Position: Q4 2020 in Review

Exane Derivatives sold out of Amarin Corp (AMRN) in Q4 2020, closing a stake of 470 shares — an estimated $39.6K sold.

Exane Derivatives first reported a position in AMRN in Q1 2020 and held it in 3 quarters. The position peaked at $67.3K in Q2 2020. 240 funds tracked by Wall St. Rank hold AMRN as of Q4 2020.

  • Exane Derivatives reported no remaining Amarin Corp position as of Q4 2020 after selling out during the quarter.
  • Exane Derivatives sold 470 Amarin Corp shares in Q4 2020, an estimated $39.6K.
  • Exane Derivatives first reported a position in Amarin Corp in Q1 2020 and held it in 3 quarters.
  • Exane Derivatives's Amarin Corp position peaked at $67.3K in Q2 2020.
  • 240 funds tracked by Wall St. Rank held Amarin Corp as of Q4 2020.

Based on Exane Derivatives's 13F filing for Q4 2020, filed 27 Jan 2021.